Vulnerabilities in Yersinia pestis caf operon are unveiled by a Salmonella vector.

PloS One
Ling CaoXinghong Yang

Abstract

During infection, Yersinia pestis uses its F1 capsule to enhance survival and cause virulence to mammalian host. Since F1 is produced in large quantities and secreted into the host tissues, it also serves as a major immune target. To hold this detrimental effect under proper control, Y. pestis expresses the caf operon (encoding the F1 capsule) in a temperature-dependent manner. However, additional properties of the caf operon limit its expression. By overexpressing the caf operon in wild-type Salmonella enterica serovar Typhimurium under a potent promoter, virulence of Salmonella was greatly attenuated both in vitro and in vivo. In contrast, expression of the caf operon under the regulation of its native promoter exhibited negligible impairment of Salmonellae virulence. In-depth investigation revealed all individual genes in the caf operon attenuated Salmonella when overexpressed. The deleterious effects of caf operon and the caf individual genes were further confirmed when they were overexpressed in Y. pestis KIM6+. This study suggests that by using a weak inducible promoter, the detrimental effects of the caf operon are minimally manifested in Y. pestis. Thus, through tight regulation of the caf operon, Y. pestis precisely ba...Continue Reading

References

Jan 1, 1997·Clinical Microbiology Reviews·R D Perry, J D Fetherston
Aug 12, 1998·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·H C GuillobelL C Ferreira
Feb 11, 1999·Journal of Bacteriology·G E Soto, S J Hultgren
May 12, 2000·JAMA : the Journal of the American Medical Association·T V InglesbyK Tonat
Jun 8, 2001·Veterinary Immunology and Immunopathology·M CalandrellaA Poli
Feb 21, 2002·Infection and Immunity·Yidong DuAke Forsberg
May 22, 2003·Advances in Experimental Medicine and Biology·Tatyana V Meka-Mechenko
Aug 19, 2003·Journal of Bacteriology·Francisco Ramos-MoralesJosep Casadesús
Mar 5, 2004·Journal of Bacteriology·Robert D PerryJacqueline D Fetherston
Mar 23, 2004·International Journal of Hygiene and Environmental Health·Björn P Zietz, Hartmut Dunkelberg
Dec 16, 2004·Proceedings of the National Academy of Sciences of the United States of America·Mark AchtmanPaul Keim
Jan 20, 2006·Molecular Microbiology·Lloyd S RobinsonMatthew R Chapman
Jan 5, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xinghong YangDavid W Pascual
Apr 10, 2007·Lancet·Michael B Prentice, Lila Rahalison
Sep 25, 2007·Journal of Bacteriology·Aleksandra E SikoraMaria Sandkvist
Oct 26, 2007·Nature Reviews. Immunology·Matthew E Call, Kai W Wucherpfennig
Mar 4, 2008·Journal of Bacteriology·Lisa M RuncoDavid G Thanassi
Mar 19, 2008·Infection and Immunity·Lauriane E QueneeOlaf Schneewind
May 10, 2008·DNA and Cell Biology·Yanping HanRuifu Yang
Nov 20, 2008·Current Protocols in Microbiology·Scott W Bearden, Robert D Perry
Mar 6, 2009·Langmuir : the ACS Journal of Surfaces and Colloids·Zhiyong SuoDavid W Pascual
Sep 19, 2009·Journal of Medical Microbiology·Megan E Merritt, Janet R Donaldson
Oct 20, 2009·Vaccine·E D Williamson
Oct 31, 2009·International Journal of Food Microbiology·Saumya Bhaduri
Nov 26, 2009·Biotechnology Advances·M Lucrecia Alvarez, Guy A Cardineau
Feb 9, 2010·Bioorganic & Medicinal Chemistry Letters·Hirotoshi UrakawaIchiro Matsuo
May 5, 2010·Protein Expression and Purification·Juliette K TinkerBritni M Arlian
Sep 28, 2010·Current Opinion in Microbiology·Martti Vaara
Dec 1, 2010·Infection and Immunity·Eric H WeeningVirginia L Miller

❮ Previous
Next ❯

Methods Mentioned

BETA
motile behavior assay

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.